Confidence interval criteria for assessment of dose proportionality

被引:328
作者
Smith, BP
Vandenhende, FR
DeSante, KA
Farid, NA
Welch, PA
Callaghan, JT
Forgue, ST
机构
[1] Lilly Lab Clin Res, Indianapolis, IN 46202 USA
[2] Lilly Dev Ctr, B-1348 Mont St Guibert, Belgium
[3] Lilly Res Labs, Drug Disposit Dept, Indianapolis, IN 46285 USA
[4] Indiana Univ, Sch Med, Dept Pharmacol, Indianapolis, IN 46202 USA
[5] Indiana Univ, Sch Med, Dept Pediat, Indianapolis, IN 46202 USA
[6] Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA
关键词
bioequivalence; dose proportionality; mixed effects model; pharmacokinetics; power model;
D O I
10.1023/A:1026451721686
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. The aim of this work was a pragmatic, statistically sound and clinically relevant approach to dose-proportionality analyses that is compatible with common study designs. Methods. Statistical estimation is used to derive a (1-alpha)% confidence interval (Cl) for the ratio of dose-normalized, geometric mean values (%,) of a pharmacokinetic variable (PK). An acceptance interval for R-dnm defining the clinically relevant, dose-proportional region is established a priori. Proportionality is declared if the CI for R-dnm is completely contained within the critical region. The approach is illustrated with mixed-effects models based on a power function of the form PK = beta (0) (.) Dose(beta1); however, the logic holds for other functional forms. Results. It was observed that the dose-proportional region delineated by a power model depends only on the dose ratio. Furthermore, a dose ratio (p(1)) can be calculated such that the Cl lies entirely within the pre-specified critical region. A larger ratio (p(2)) may exist such that the CI lies completely outside that region. The approach supports inferences about the PK response that are not constrained to the exact dose levels studied. Conclusion. The proposed method enhances the information from a clinical dose-proportionality study and helps to standardize decision rules.
引用
收藏
页码:1278 / 1283
页数:6
相关论文
共 14 条
  • [1] Pharmacokinetics of testosterone in hypogonadal men after transdermal delivery: Influence of dose
    Brocks, DR
    Meikle, AW
    Boike, SC
    Mazer, NA
    Zariffa, N
    Audet, PR
    Jorkasky, DK
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 36 (08) : 732 - 739
  • [2] DOSE PROPORTIONAL PHARMACOKINETICS OF ALPROSTADIL (PROSTAGLANDIN E(1)) IN HEALTHY-VOLUNTEERS FOLLOWING INTRAVENOUS-INFUSION
    CAWELLO, W
    LEONHARDT, A
    SCHWEER, H
    SEYBERTH, HW
    BONN, R
    LOMELI, AL
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 40 (03) : 273 - 276
  • [3] AREA-DOSE RELATIONSHIPS IN NONLINEAR MODELS
    CHAU, NP
    [J]. JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1976, 4 (06): : 537 - 551
  • [4] CHEN ML, 1992, STAT PROCEDURES BIOE
  • [5] Finney D. J., 1978, STAT METHOD BIOL ASS
  • [6] Gough K., 1995, Drug Inf J, V29, P1039, DOI DOI 10.1177/009286159502900324
  • [7] HAYNES JD, 1989, P BIOPH SECT AM STAT, P85
  • [8] INTRODUCTION OF A COMPOSITE PARAMETER TO THE PHARMACOKINETICS OF VENLAFAXINE AND ITS ACTIVE O-DESMETHYL METABOLITE
    KLAMERUS, KJ
    MALONEY, K
    RUDOLPH, RL
    SISENWINE, SF
    JUSKO, WJ
    CHIANG, ST
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 32 (08) : 716 - 724
  • [9] PHARMACOKINETIC PROFILES OF CIPROFLOXACIN AFTER SINGLE INTRAVENOUS AND ORAL DOSES
    LETTIERI, JT
    ROGGE, MC
    KAISER, L
    ECHOLS, RM
    HELLER, AH
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (05) : 993 - 996
  • [10] ABSOLUTE BIOAVAILABILITY AND DOSE PROPORTIONALITY OF BETAXOLOL IN NORMAL HEALTHY-SUBJECTS
    LUDDEN, TM
    BOYLE, DA
    GIESEKER, D
    KENNEDY, GT
    CRAWFORD, MH
    LUDDEN, LK
    CLEMENTI, WA
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 1988, 77 (09) : 779 - 783